Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis

Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis

Abstract Objective To investigate the efficacy and safety of docetaxel chemotherapy combined with androgen-deprivation therapy for patients with high-volume disease metastatic hormone-sensitive prostate cancer. Methods 153 cases of high-volume disease metastatic hormone-sensitive prostate cancer in...

Full description

Bibliographic Details
Main Authors:	Zhuifeng Guo, Xuwei Lu, Fan Yang, Liang Qin, Ning Yang, Jiawen Wu, Hang Wang
Format:	Article
Language:	English
Published:	BMC 2022-08-01
Series:	European Journal of Medical Research
Subjects:	Prostate cancer High-volume disease Metastatic Hormone-sensitive Docetaxel Androgen-deprivation therapy
Online Access:	https://doi.org/10.1186/s40001-022-00773-1

Similar Items

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
by: Hu L, et al.
Published: (2020-06-01)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
by: Kenichi Hata, et al.
Published: (2022-11-01)

Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer
by: S. V. Popov
Published: (2019-12-01)

Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
by: Whi-An Kwon, et al.
Published: (2019-05-01)

Choice of treatment options for metastatic hormone-sensitive prostate cancer
by: R. A. Gafanov, et al.
Published: (2020-12-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Body composition and metastatic prostate cancer survivorship
by: Adriana M Coletta, et al.
Published: (2021-01-01)

Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
by: Natalia Jiménez, et al.
Published: (2022-09-01)

POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice
by: Ietsen de Groot, et al.
Published: (2021-11-01)

Novel androgen receptor inhibitors for metastatic hormone-sensitive prostate cancer: Current application and future perspectives
by: Qi-Dong Xia, et al.
Published: (2023-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
by: Kyungchan Min, et al.
Published: (2020-04-01)

Treatment of Hormone Resistance with Docetaxel in Metastatic Prostate Cancer Patients: Results of a Clinical Experience at Omid Hospital, Isfahan, Iran
by: Mina Tajvidi, et al.
Published: (2017-01-01)

Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world
by: Yutong Lu, et al.
Published: (2024-04-01)

Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis
by: Francesco Fiorica, et al.
Published: (2022-12-01)

Efficacy and Prognostic Factors of Docetaxel Combined with ADT on Metastatic Hormone-sensitive Prostate Cancer Patients
by: LIU Sanhe, et al.
Published: (2019-06-01)

Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score
by: Heba Taha, et al.
Published: (2022-10-01)

Oligometastatic Prostate Cancer: A Comparison between Multimodality Treatment vs. Androgen Deprivation Therapy Alone
by: Francesco A. Mistretta, et al.
Published: (2022-05-01)

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy
by: Masaki eShiota, et al.
Published: (2016-01-01)

Impact of Androgen Deprivation Therapy on Cardiovascular Outcomes in Prostate Cancer
by: Laurence Klotz, et al.
Published: (2022-07-01)

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
by: Leandro Blas, et al.
Published: (2022-01-01)

Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform
by: Pawel Rajwa, et al.
Published: (2024-05-01)

Lacrimal sac adenocarcinoma managed with androgen deprivation
by: David H. Abramson, et al.
Published: (2020-09-01)

Gemcitabine plus platinum versus docetaxel plus platinum as first line therapy for metastatic nasopharyngeal carcinoma: A randomized clinical study
by: Hui Yang, et al.
Published: (2021-01-01)

Current problems in the first-line treatment of metastatic breast cancer: focus on the role of docetaxel
by: Filippo Montemurro
Published: (2010-09-01)

Follicle Stimulating Hormone Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer
by: Kaleem Atchia, et al.
Published: (2022-03-01)

Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis
by: Naiki T, et al.
Published: (2018-09-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis
by: Xin Hu, et al.
Published: (2019-12-01)

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
by: Yuki Yoshikawa, et al.
Published: (2022-12-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma—A Retrospective Study
by: Paul V. Viscuse, et al.
Published: (2019-08-01)

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer
by: Li Q, et al.
Published: (2019-12-01)

Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer
by: Judith Passildas‐Jahanmohan, et al.
Published: (2021-04-01)

Steroid Hormone Biosynthesis Metabolism Is Associated With Fatigue Related to Androgen Deprivation Therapy for Prostate Cancer
by: Li Rebekah Feng, et al.
Published: (2021-05-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)